Search

Cookie policy

Introduction
When you visit the EHA website and/or EHA’s resource platform(s) (this includes all websites and pages, with the exemption of www. t2evolve.

Read more

Novel basis for chemoresistance in AML: DNMT3A R882 mutations promote chemoresistance and residual disease through impaired DNA damage sensing

Although most acute myeloid leukemia (AML) patients initially respond to chemotherapy, the majority subsequently relapses and succumbs to refractory disease. Residual leukemic cells that survived chemotherapy may persist over time and later cause the disease to come back.

Read more

EHA Awards

Nominations closed on January 15, 2025. Since 1999, EHA has used its awards program to acknowledge successes within our global community of hematologists. You can read about our many prestigious winners in the previous awards section.

Read more

EHA-BSH joint membership

Save money and time by becoming a joint member of EHA and the British Society of Haematology. We've joined forces with the British Society of Haematology (BSH) to offer a special joint membership deal.

Read more

Abstract & travel grant submission

Abstract submission is closed

Abstract procedurePlease note that the submission of an abstract constitutes a formal commitment by the presenting author to present the abstract (if accepted) orally or as a poster in the session at the time assigned by the…

Read more

Major Conference: innovation and patient access to personalised medicine

The meeting will bring together researchers, patients, physicians, regulators and politicians, to explore the current barriers and how they can be dismantled.

Read more

How can I start contributing?

Getting started is easy! Here are a few good-to-know tips, that will help you navigate the different aspects of the EHA Hub.

Read more